Skip to content
MamaGLP — home

Evidence review

Ozempic vagina: what it means, and what is known

A phrase the internet invented, answered calmly: what women are describing, what the FDA labels do and do not say, and where the evidence genuinely runs out.

Written by Camila Rael, editoraa mom, not a clinician treating you

Every medical claim is cited to its primary source — the clinical trial or the FDA label — so you can open it and check it yourself. No one on this team is your healthcare professional. What follows is friendly information, never medical advice.

On this page

Where the phrase came from

If you searched this, you probably saw the words somewhere alarming and felt your stomach drop a little. Let me start with the reassuring part: "Ozempic vagina" is not a medical diagnosis. It is a phrase the internet made up, in the same family as "Ozempic face" and "Ozempic butt" — a shorthand for changes women noticed during rapid weight loss and then gave a name.

That does not mean women are imagining things. It means the name arrived before the evidence did, which is a very different problem, and it is worth separating the two calmly.

What the drug labels actually say

I went and read the current prescribing information rather than repeating what circulates.

The label for Wegovy (semaglutide) contains no mention of vaginal changes, vulvovaginal symptoms, candidiasis, or genital fungal infection — none1. The label for Zepbound (tirzepatide) contains none of those terms either2.

So whatever women are describing, it is not a documented, labeled effect of these medicines. If it were common and clearly caused by the drug, it would be in the adverse reactions table, because far less dramatic things are — belching is in there.

One genuine point of confusion is worth clearing up. There is a diabetes drug class strongly associated with genital yeast infections: SGLT2 inhibitors, such as empagliflozin, whose label carries a dedicated warning section for genital mycotic infections3. They work by pushing sugar into your urine, and yeast feeds on it. Many people with type 2 diabetes take one of those alongside a GLP-1. If that is you, the risk in your cabinet is real — it is just attached to the other prescription.

So what are women describing?

Mostly three things: dryness, a change in sensation, and a sense that the tissue itself looks or feels different. Here is the honest map of what might explain that.

Losing weight quickly changes tissue everywhere, including there. The face and the body change visibly; there is no reason the vulva would be exempt. This is the most likely explanation and also the least studied.

Oestrogen. Vaginal dryness, thinning and irritation are the hallmark of low oestrogen — the condition clinicians call genitourinary syndrome of menopause, which has an international consensus behind its definition and treatment4, and which older literature described as vulvovaginal atrophy5. If you are in your forties or fifties, this may be arriving at the same time as your GLP-1 and getting blamed on it.

The closest real evidence comes from other weight loss, not from these drugs. Sexual function after major weight loss has been studied in bariatric surgery patients, including a systematic review and meta-analysis6. That is the nearest analogue we have — and it is an analogue, not a study of GLP-1s.

The part I will not dress up

Nobody has properly studied the vulvovaginal effects of GLP-1 medicines in women. There is no trial. There is no cohort. Every mechanism above is borrowed from a different setting and applied here because it is plausible, not because it has been demonstrated.

That is the truthful answer, and you deserve it more than you deserve a confident one. Anyone telling you exactly what these drugs do to your vulva is going further than the evidence allows — in either direction, including anyone telling you nothing at all is happening.

What to do with that

  • If it is dryness or irritation, that is treatable, and it is treatable regardless of what caused it. Vaginal moisturisers, lubricants and — where appropriate — local oestrogen are established options. Bring it up. Clinicians hear this constantly.
  • If it is itching, unusual discharge or a smell, that sounds more like an infection than a tissue change, and infections get tested for rather than guessed at.
  • If you take an SGLT2 inhibitor as well, say so. It changes what your clinician is thinking about.
  • If it arrived alongside hot flushes, sleep changes or cycle changes, the perimenopause conversation may be the one you actually need.

None of this is a reason to stop a medicine that is working for you, and none of it is a reason to suffer quietly with something fixable.

If you want the wider picture, I have written about the side effects and how to manage them, about how your body changes after pregnancy, and about feeling at home in a changing body. How I evaluate providers is set out in the methodology.

This is educational, not medical advice. These medicines are not for use during pregnancy or while trying to conceive.

Frequently asked questions

What is “Ozempic vagina”?

It is an internet phrase, not a medical diagnosis — the same kind of shorthand as “Ozempic face”. It refers to dryness, changed sensation or a different appearance that some women notice during rapid weight loss on a GLP-1. The current FDA labels for Wegovy and Zepbound do not list any vaginal or vulvovaginal effect at all, so it is a description of what women report rather than a documented effect of the medicine.

Do GLP-1 medicines cause vaginal dryness?

There is no trial showing that they do, and nothing on the labels. The plausible explanations are rapid weight loss changing tissue, or low oestrogen — the genitourinary syndrome of menopause — arriving at the same time and being attributed to the drug. The closest real evidence about major weight loss and sexual function comes from bariatric surgery research, which is an analogue rather than a study of these medicines.

Could it be a yeast infection instead?

If there is itching, unusual discharge or a smell, that sounds more like an infection than a tissue change, and it should be tested rather than assumed. Worth knowing: the diabetes drug class strongly associated with genital yeast infections is SGLT2 inhibitors, not GLP-1s. Many people take one of each, so mention everything you are on.

Should I stop my GLP-1 because of this?

That is a decision for you and your clinician, but nothing here is a reason to stop a medicine that is working. Dryness and irritation are treatable in their own right — moisturisers, lubricants and, where appropriate, local oestrogen are established options — regardless of what caused them.

References

  1. U.S. Food and Drug Administration (2025). Wegovy (semaglutide) injection — Prescribing Information (no vaginal, vulvovaginal, candidiasis or genital mycotic infection listed). DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. U.S. Food and Drug Administration (2025). Zepbound (tirzepatide) injection — Prescribing Information (no vaginal or genital mycotic infection listed). DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  3. U.S. Food and Drug Administration (2025). Jardiance (empagliflozin) tablets — Prescribing Information, Warnings 5.6 Genital Mycotic Infections. DailyMed / FDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faf3dd6a-9cd0-39fe-0d68-4e0d3f80cd3f
  4. Simon JA, Nappi RE, Chedraui P, et al. (2026). Genitourinary syndrome of menopause (GSM): recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sexual Medicine Reviews. https://pubmed.ncbi.nlm.nih.gov/40981832/
  5. Mac Bride MB, Rhodes DJ, Shuster LT. (2010). Vulvovaginal atrophy. Mayo Clinic Proceedings. https://pubmed.ncbi.nlm.nih.gov/20042564/
  6. Loh HH, Shahar MA, Loh HS, Yee A. (2022). Female sexual dysfunction after bariatric surgery in women with obesity: A systematic review and meta-analysis. Scandinavian Journal of Surgery. https://pubmed.ncbi.nlm.nih.gov/35253540/

Friendly information, not a prescription. Everything on MamaGLP is here to help you understand your options and ask better questions — it is not a diagnosis, not a treatment plan, and not a nudge to start or stop anything. Only a licensed healthcare professional who knows your history and your goals can tell you what is right for you, so please talk with one before acting on a single word of this.